Corvus Pharmaceuticals CRVS

Dr. Miller has served as our President and Chief Executive Officer since February 2014 and chairman of our Board since January 2014 and co-founded the Company. From April 2012 to October 2014, Dr. Miller was Chairman and Chief Executive Officer of Graphea, Inc., a privately held chemical company, which he founded. Dr. Miller served as Chief Commercialization Officer, Associate Dean and Research Professor in Chemistry at The University of Texas at Austin from September 2010 to December 2011. Dr. Miller founded Principia Biopharma Inc., a privately held biopharmaceutical company, and served as its President and Chief Executive Officer and a member of its board of directors from January 2009 to February 2011. He served as President, Chief Executive Officer and Director of Pharmacyclics, Inc., a public biopharmaceutical company, from 1991, when he co-founded the company, to 2008. At Pharmacyclics, Dr. Miller led the initial discovery and development efforts for ibrutinib. Dr. Miller was a co founder, Vice President and Director of IDEC Pharmaceuticals Corporation, a biotechnology company that merged with Biogen, Inc. in June 2003, where he led research efforts on lymphoma leading to the development of rituximab. Dr. Miller was an Adjunct Clinical Professor of Medicine (Oncology) at Stanford University Medical Center from 1991 to 2023. Dr. Miller received a B.A. in Chemistry from Franklin & Marshall College and an M.D. summa cum laude from the State University of New York Medical School. He is board certified in both Internal Medicine and Medical Oncology.

Mr. Lea has served as our Chief Financial Officer since November 2014. Mr. Lea was a financial consultant from 2009 to November 2014. From 1998 to 2008, Mr. Lea served as Chief Financial Officer of Pharmacyclics, Inc., a biopharmaceutical company. From 1996 to 1997, he was a financial consultant. From 1986 to 1996, Mr. Lea served as Chief Financial Officer of Margaux, Inc., a refrigeration equipment manufacturer. He received a B.S. in Agricultural Economics from the University of California, Davis and an M.B.A. from the Anderson School at the University of California, Los Angeles.

Dr. Jones has served as our Senior Vice President, Pharmaceutical Development since December 2019 and as our Vice President, Pharmaceutical Development from December 2014 to December 2019. Dr. Jones was Director of Global Regulatory Affairs in the oncology business unit of Sanofi US, LLC, a pharmaceutical company, from December 2012 to December 2014. From 2008 to March 2012, Dr. Jones was Director of Project Management & Regulatory at Pharmacyclics, Inc., a biopharmaceutical company. Dr. Jones served as Associate Director of Development for Plexxikon, Inc., a pharmaceutical company, from 2005 to 2007. From 2002 to 2005, he was Senior Project Manager at Vertex Pharmaceuticals, Inc., a biotechnology company. Dr. Jones received a B.S. and a Ph.D. in Chemistry from the University of Cincinnati and an M.B.A. from Babson College. He completed a post-doctoral fellowship at the University of Oxford.

Mr. Moore has served as a member of our Board since October 2025. Mr. Moore served as Executive Vice President, U.S. Operations and Business Development and President of Novo Nordisk Inc., the U.S. affiliate of Novo Nordisk, a public pharmaceutical company, from January 2025 to February 2026. He previously served as Executive Vice President of Corporate Development at Novo Nordisk from March 2023 to January 2025, and as Senior Vice President of Corporate Development at Novo Nordisk from September 2022 to March 2023. Prior to rejoining Novo Nordisk, Mr. Moore was a Partner at Gurnet Point Capital, a private healthcare investment firm, from March 2020 to September 2022, where he focused on healthcare investments across multiple stages of development. From May 2019 to March 2020, he served as Chief Executive Officer of a subsidiary of Roivant Sciences, a public biopharmaceutical company. Earlier in his career, Mr. Moore held senior commercial roles at Novo Nordisk from 2017 to 2019. Mr. Moore has also held leadership positions at several public and private biopharmaceutical and healthcare companies, where he focused on commercial strategy, business development and operations. Mr. Moore holds an M.B.A. in Marketing from Lehigh University and a Bachelor of Science from Towson University.

Mr. van den Broek has served as a member of our Board since April 2025. Mr. van den Broek currently serves as a managing partner of HSMR Advisors, LLC, an investment advisory firm, since February 2004. He currently serves on the board of directors for Pulse Biosciences, Inc., a publicly traded biotechnology company, since August 2020 and previously served on the board of directors of Cogstate Ltd, a publicly traded neuroscience company, from April 2009 to April 2025. Mr. van den Broek received an A.B. from Harvard University and is a Chartered Financial Analyst.

Dr. Grais has served as a member of our Board since January 2019. Dr. Grais previously served as President and Chief Executive Officer of Ocera Therapeutics, Inc. from June 2012 to December 2017 and as a member of its board of directors from January 2008 through December 2017. Prior to her employment by Ocera, Dr. Grais served as a managing member at InterWest Partners, a venture capital firm, from May 2005 until February 2011. From July 1998 to July 2003, Dr. Grais was a founder and executive vice president of SGX Pharmaceuticals Inc., a drug discovery company focusing on new treatments for cancer. Prior to that, she was a corporate attorney at Wilson Sonsini Goodrich & Rosati, where she practiced in such areas as venture financings, public offerings and strategic partnerships. Before practicing law, Dr. Grais worked as an assistant clinical professor of Internal Medicine and Critical Care at the University of California, San Francisco. She currently serves on the board of directors of ICON plc, a public contract research organization, Collective Health, a private healthcare services company and Iolyx Therapeutics, Inc., a private biotechnology company. Dr. Grais received a B.A. from Yale University, an M.D. from Yale Medical School and a J.D. from Stanford Law School.

Dr. Thompson has served as a member of our Board since November 2014 and co-founded the Company. Dr. Thompson is a Member at OrbiMed Advisors LLC, an investment firm. Dr. Thompson currently serves on the boards of directors of ARS Pharmaceuticals, Inc. (formerly Silverback Therapeutics, Inc.), Edgewise Therapeutics, Inc., and Sionna Therapeutics, Inc., as well as several private companies. Previously, Dr. Thompson served on the boards of Alpine Immune Sciences, Inc., Decibel Therapeutics, Inc., Janux Therapeutics, Inc., and PMV Pharmaceuticals, Inc. Dr. Thompson also previously served in executive leadership roles at Trubion Pharmaceuticals, Inc., Chiron Corporation, and Becton, Dickinson and Company. Dr. Thompson is an Affiliate Professor of Neurosurgery at the University of Washington. In addition, Dr. Thompson holds a Sc. B. in Molecular Biology and Mathematics from Brown University and an M.D. from Brown University Medical School.

Mr. Arcara has served as our Chief Business Officer since February 2024. Mr. Arcara was a corporate development consultant from September 2023 to January 2024. From 2011 to August 2023 Mr. Arcara held roles of increasing responsibility with Teva Pharmaceuticals, a pharmaceutical company, most recently as Senior Vice President, Global Marketing, Portfolio and Strategy. From 2007 to 2010, he served as Vice President, Business Development at Neuromed, a pharmaceutical company. From 2006 to 2007 Mr. Arcara served as Executive Director, New Products Marketing at Wyeth Pharmaceuticals, Inc., a pharmaceutical company, and from 2000 to 2005 as Vice President, Commercial at InKine Pharmaceuticals, a pharmaceutical company. Mr. Arcara received a Bachelor of Business Administration degree from the University of Wisconsin Madison, and an M.B.A. from the Anderson School at the University of California, Los Angeles.

On April 22, 2026, the Board of Directors of Corvus Pharmaceuticals, Inc., upon the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Andrew C. Chan, M.D., Ph.D., to the Board, effective April 23, 2026. Dr. Chan is a physician-scientist with extensive leadership experience in industry and academic medicine. He joined Genentech in 2001 and spent more than two decades with the company, most recently serving as Senior Vice President, Research Biology from 2010 to 2025. In this role, he led biological research across all therapeutic areas, contributing to the development of several FDA-approved medicines for oncology, neurology and immunology. Dr. Chan has also held longstanding academic and clinical roles at the University of California, San Francisco (UCSF). He has served as an Associate Adjunct Professor of Medicine in the Division of Rheumatology since 2020 and practiced as an attending physician at UCSF Long-Moffitt Hospital and Barnes Hospital. Prior to UCSF, he was an Associate Professor of Medicine at Washington University School of Medicine and an Associate Investigator of the Howard Hughes Medical Institute. Dr. Chan earned his B.A. and M.S. in Chemistry from Northwestern University and his M.D. and Ph.D. from Washington University School of Medicine.